Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials – an empirical analysis of bias

Published:2019-10-14 Issue:1 Volume:59 Page:90-95
ISSN:0284-186X
Container-title:Acta Oncologica
language:en
Short-container-title:Acta Oncologica

Author:

Snyders Kelli¹,Cho Doah²,Hong Jun Hee¹,Lord Sally²³,Asher Rebecca²,Marschner Ian²⁴,Lee Chee Khoon¹²

Affiliation:

1. Cancer Care Centre, St George Hospital, Kogarah, Australia;

2. National Health and Medical Research Council Clinical Trials Centre, Camperdown, Australia;

3. School of Medicine, The University of Norte Dame, Darlinghurst, Australia;

4. Department of Statistics, Macquarie University, Sydney, Australia

Publisher

Informa UK Limited

Subject

Radiology Nuclear Medicine and imaging,Oncology,Hematology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/0284186X.2019.1674452

Reference23 articles.

1. Genetic alterations defining NSCLC subtypes and their therapeutic implications

2. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

3. AURA 3: the last word on chemotherapy as a control arm in EGFR mutant NSCLC?

4. Sufficiency of Single‐Arm Studies to Support Registration of Targeted Agents in Molecularly Selected Patients with Cancer: Lessons from the Clinical Development of Crizotinib

5. The role of nonrandomized trials in the evaluation of oncology drugs

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Framework for the Use of External Controls to Evaluate Treatment Outcomes in Precision Oncology Trials;JCO Precision Oncology;2024-02

2. Surrogate endpoints for HTA decisions of breast cancer drugs: utility and pitfalls;Current Opinion in Oncology;2023-07-24

3. Substituting a randomised placebo control group with a historical placebo control in an endometriosis pain trial: a case study re-evaluating trial data using historical control data from another trial;BMJ Open;2023-07

4. Model‐based meta‐analysis of non‐small cell lung cancer with standard of care PD‐1 inhibitors and chemotherapy for early development decision making;CPT: Pharmacometrics & Systems Pharmacology;2023-01-31

5. Summarising salient information on historical controls: A structured assessment of validity and comparability across studies;Clinical Trials;2020-09-21

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3